Boulder-based oncology company Enliven Therapeutics raises $55M Series A
BOULDER — Enliven Therapeutics Inc., a Boulder-based cancer-drug developer, is exiting from stealth operations by announcing that it raised $55 […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
Enliven Therapeutics merger with Imara coincides with $165 million raise
BOULDER — Last week was a big one for Boulder-based oncology drug developer Enliven Therapeutics Inc., which inked a merger…
Enliven Therapeutics closes merger, $165M raise
BOULDER — Boulder-based oncology drug developer Enliven Therapeutics Inc. has completed its merger with Boston pharmaceutical company Imara Inc., a…
Boulder’s Arpeggio Bioscience raises $17M Series A to bolster drug trials
BOULDER — Arpeggio Bioscience Inc., a preclinical-stage pharmaceutical company founded by University of Colorado Boulder doctoral program graduates, has raised…
OnKure aims for $60M in new funding round
BOULDER — Biopharmaceutical company OnKure Inc. has raised nearly $54 million of a $60 million funding round, according to documents…